Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of CDK4/6 Inhibitor Ribociclib (LEE011) Combined With Gemcitabine in Patients With Advanced Solid Tumors

NCT03237390 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03237390
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03237390 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of CDK4/6 Inhibitor Ribociclib (LEE011) Combined With Gemcitabine in Patients With Advanced Solid Tumors
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Completed
Start date
January 4, 2018
Completion date
May 17, 2022
Enrollment
43 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant solid neoplasm, metastatic malignant solid neoplasm